Y LynnWangMDPhD, FCAP

PubMed

• 2 citations
  SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker.
  Wenjun Wu, Pin Lu, Priyal Patel, Ji Ma, Kathy Qi Cai
  Oncogene. 2023-02-01
• Cardiovascular Involvement of a CD138-Negative Anaplastic Myeloma: A Diagnostic Dilemma.
  Jui Choudhuri, Victor Janmey, Juan Ding, Denise Dailey, Yang Shi
  Hematology Reports. 2023-01-18
• 38 citations
  Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
  Shazia Nakhoda, Aldana Vistarop, Y Lynn Wang
  British Journal of Haematology. 2023-01-01

Journal Articles

• Cyclophilin A-regulated ubiquitination is critical for RIG-I-mediated antiviral immune responses  
  Liu W, Li J, Zheng W, Shang Y, Zhao Z, Wang S, Bi Y, Zhang S, Xu C, Duan Z, Zhang L, Wang YL, Jiang Z, Liu W, and Sun L, eLife, 1/1/2017
• Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL  
  Kadri S, Lee J, Fitzpatrick C, Galanina N, Sukhanova M, Venkataraman G, Sharma S, Long B, Petras K, Theissen M, Ming M, Kobzev Y, Kang W, Guo A, Wang W, Niu N, Weiner ..., Blood Advances, 1/1/2017
• B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy  
  Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, Segal J, Li S, Zhou S, Santos D, Richard S, Sharma S, Chen W, Oriabure O, Liu Y, Huang S, Guo H, Chen Z, Tao W, Li ..., Clin Can Res, 1/1/2017
• HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment  
  Guo A, Lu P, Lee J, Zhen CJ, Chiosis G, Wang YL, Oncogene, 1/1/2017
• Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by ...  
  Guo A, Lu P, Coffey G, Conley P, Pandey A, and Wang YL, Oncotarget, 1/1/2017
• Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays  
  Kadri S, Long BC, Mujacic I, Zhen CJ, Wurst MN, Sharma S, McDonald N, Niu N, Benhamed S, Tuteja J, Seiwert T, White K, McNerney ME, Fitzpatrick C, Wang YL, Furtado LV,..., J. Mol. Diagn., 1/1/2017
• Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma  
  Ma J, Xing W, Coffey G, Dresser K, Lu K, Guo A, Raca G, Pandey A, Conley P, Yu H and Wang YL, Oncotarget, 1/1/2015
• Functional Characterization of BTKC481S mutation that confers ibrutinib resistance: Exploration of alternative kinase inhibitors  
  Cheng S, Guo A, Lu P, Ma J, Coleman M, and Wang YL, Leukemia, 1/1/2015
• Ibrutinib resistance in chronic lymphocytic leukemia  
  Furman RR*, Cheng S*, Lu P*, Setty M, Perez A, Guo A, Racchumi J, Xu G, Ma J, Coleman M, Buggy J, Leslie C, and Wang YL, N Engl J Med, 1/1/2014
• BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity  
  Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, Liu M, Buggy JJ, Furman RR, and Wang YL, Leukemia, 1/1/2014
• Molecular monitoring of CML: International Standardization of BCR-ABL quantification  
  Zhen CJ and Wang YL, J. Mol. Diagn., 1/1/2013
• Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del (5q)  
  Geyer JT, Verma S, Subramaniyam S, Mathew, Wang YL, Racchumi J, Espinal-Witter R, Knowles DM and Orazi A, Hum Pathol, 1/1/2013
• Laboratory detection of JAK2V617F in human myeloproliferative neoplasms  
  Kui JS, Espinal–Witter R, and Wang YL, Methods Mol Biol, 1/1/2013
• Molecular and Immunohistochemical Detection of Kaposi Sarcoma Herpesvirus / Human Herpesvirus-8  
  Chadburn A, Wilson J, and Wang YL, Methods Mol Biol, 1/1/2013
• Strongyloides stercoralis infection presenting as an unusual cause of massive upper gastrointestinal bleeding in an immunosuppressed patient: a case report  
  Jaka H, Koy M, Egan JP, Meda JR, Mirambo M, Mazigo HD, Kabangila R, Wang YL, Mueller A, Peck RN, Mchembe MD, Chalya PL, Trop Doct, 1/1/2013
• Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies  
  Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Blasberg R, Melnick A, Cerchietti L, Chiosis G, Wang YL*, Cesarman E*, Blood, 1/1/2013
• Laboratory Practice Guidelines for Detecting and Reporting JAK2 and MPL Mutations in Myeloproliferative Neoplasms: A Report of the Association for Molecular Pathology  
  Gong JZ, Cook JR, Greiner TC, Hedvat C, Hill CE, Lim MS, Longtine JA, Sabath D, Wang YL, J. Mol. Diagn., 1/1/2013
• JAK2V617F allele burden is reduced by busulfan therapy: A new observation using an old drug  
  Kuriakose ET, Gjoni S, Wang YL, Baumann R, Jones A, Cross NCP, and Silver RT, Haematologica, 1/1/2013
• Certification in Molecular Pathology in the United States: An Update from the Association for Molecular Pathology Training and Education Committee  
  Mackinnon AC, Wang YL, Sahota A, Yeung CC, and Weck KE, J. Mol. Diagn., 1/1/2012
• Splenic Extramedullary Hematopoiesis in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: Heterogeneous Morphology and Cytologic Composition  
  Prakash S, Hoffman R, Barouk S, Wang YL, Knowles DM, and Orazi A, Mod Pathol, 1/1/2012
• Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera  
  Kuriakose ET, Vandris K, Wang YL, Chow W, Jones AV, Christos PJ, Cross NCP, and Silver RT, Haematologica, 1/1/2012
• SYK inhibition and response prediction in diffuse large B-cell lymphoma  
  Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P, Pandey A, Melnick AM, Sinha U and Wang YL, Blood, 1/1/2011
• Translating trial-based molecular monitoring into clinical practice: Importance of International Standards and Practical Considerations for Community Practitioners  
  Akard LP and Wang YL, Clinical Lymphoma, Myeloma & Leukemia, 1/1/2011
• JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy  
  Silver RT, Vandris K, Wang YL, Adriano F, Jones AV, Christos PJ, and Cross NC, Leuk Res, 1/1/2011
• Establishment of the 1st World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA  
  White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Wang YL, Branford S, Müller MC, Beaufils N, Beillard E, Colomer D, Dvorakova D, Ehrencrona H, Goh H-G, Housni HE, J..., Blood, 1/1/2010
• Join now to see all

Books/Book Chapters

• Knowles’ Neoplastic Hematopathology 
  Chapter: Antigen Receptor Genes: Structure, Function, and Molecular Analysis in Clinical Applications 
  Page 156 - 167Wang YL, Cesarman E, and Knowles DMEdition 3rd,2013

Lectures

• Inhibition of B-Cell Receptor Signaling Disrupts Cell Adhesion in Mantle Cell Lymphoma Via RAC2 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib resistance in CLL and exploration of alternative therapies 
  1/2/2018
• Ibrutinib resistance and exploration of alternative therapies using a personalized CLL Rx model 
  Chicago, IL - 1/26/2017
• Precision medicine: Molecular targeted therapies in non-Hodgkin lymphoma 
  1/19/2017
• Clonal Evolution Underlying Leukemia Progression and Richter Transformation in Ibrutinib-relapsed CLL Patients 
  Cancun, Mexico - 1/19/2017
• Ibrutinib Resistance in CLL 
  1/3/2017
• Tyrosine kinase inhibition in diffuse large B-cell lymphoma 
  1/15/2016
• Ibrutinib resistance- Mechanisms and options 
  1/14/2016
• Monitoring Deep Molecular Response: A sensitive and robust FDA cleared assay for CML 
  1/13/2016
• Ibrutinib resistance and implications for clinical practice 
  1/1/2016
• Precision medicine in lymphoma: Mutations and pathway anomalies leading to ibrutinib resistance in CLL and non- Hodgkin lymphomas 
  Tucson, AZ - 1/21/2015
• Laboratory Investigation of Ibrutinib Resistance in CLL 
  1/5/2015
• Characterization of Ibrutinib Sensitivity and Resistance in CLL 
  South San Francisco, CA - 1/25/2014
• Mechanisms of Ibrutinib Sensitivity and Resistance in CLL 
  1/24/2014
• Genomic and Molecular Pathology at the University of Chicago Medicine 
  1/17/2014
• Unmutated vs mutated CLL:  Molecular basis for their differential clinical response to ibrutinib treatment 
  1/12/2014
• Molecularly Targeted Therapies in Diffuse Large B-cell Lymphoma 
  1/10/2014
• Molecular Diagnostic Methods in Oncology 
  1/9/2014
• Signaling pathways in CLL: Identification of relevant in vivo drug targets 
  1/7/2014
• Molecular Monitoring of CML: International Standardization of BCR-ABL1 Quantification 
  1/1/2014
• Impact of genomic studies on the development of molecularly targeted cancer therapy 
  1/23/2013
• A Novel Mutation in Bruton Tyrosine Kinase Confers Acquired Resistance to Ibrutinib (PCI-32765) in Chronic Lymphocytic Leukemia 
  1/15/2013
• Molecular Monitoring of CML: Reporting BCR-ABL Quantification on International Scale 
  1/3/2013
• Response and resistance of MCL cells to BTK inhibition 
  1/1/2013
• Key Signaling Pathways That Determine Clinical Response To Treatment of Chronic Lymphocytic Leukemia 
  1/25/2012
• Join now to see all

Other

• New challenges and personalized therapies in CLL 
  Galanina N, Wang YL and Smith SM, Frontline, Lymphoma Research Foundation Newsletter
  1/1/2015
• Interviewed and featured in Oncology.TV on “Evaluating Cerdulatinib in Diffuse large B Cell Lymphoma” 
  
  http://oncology.tv/OncologyTVNetwork/TabId/1455/VideoId/1541/Dr-Lynn-Wang-Discusses-Evaluating-Cerdulatinib-In-Diffuse-Large-B-Cell-Lymphoma.aspx
  1/1/2015
• NCI Cancer Center News: Tiny mutation triggers drug resistance for patients with one type of leukemia 
  
  1/1/2014
• University of Chicago News Release: Tiny mutation triggers drug resistance for patients with one type of leukemia 
  UCHospitals
  http://www.uchospitals.edu/news/2014/20140528-leukemia.html
  1/1/2014
• Tiny mutation triggers drug resistance for patients with one type of leukemia 
  Science Life
  https://sciencelife.uchospitals.edu/2014/06/02/tiny-mutation-triggers-drug-resistance-for-patients-with-one-type-of-leukemia/
  1/1/2014
• Mutation causes ibrutinib resistance in CLL 
  Hematology Times
  http://www.hematologytimes.com/p_article.do?id=4188
  1/1/2014
• Interviewed and featured in OncUView® TV on “Dual SYK/JAK Inhibition Has a Broader Anti-Tumor Activity in Both ABC and GCB Types of Diffuse Large B Cell Lymphoma” (acc... 
  
  https://www.youtube.com/watch?feature=player_detailpage&v=WH2GpSnazQ
  1/1/2013
• Quoted and pictured in “Class Action For Myeloproliferative Disorders” by Dr. William Check 
  Wang YL, CAP TODAY
  1/1/2008
• Join now to see all